Shares of Ligand Pharmaceuticals Inc (LGND) have recently traded at $184.49, surpassing the average 12-month analyst target price of $184.28. This change comes amid a mix of analyst predictions, with one projecting as low as $164.00 and another as high as $206.00, resulting in a standard deviation of $14.162.
Among analysts covering Ligand, there are currently 6 strong buy ratings and 1 buy rating, while no hold, sell, or strong sell ratings have been given. The average rating stands at 1.14, indicating a favorable outlook for the stock.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
